ADAR1 Capital Management »

Dyne Therapeutics shares owned by ADAR1 Capital Management

Quarter-by-quarter ownership of Dyne Therapeutics (DYN) shares owned by ADAR1 Capital Management from 13F filings

Historical chart of ADAR1 Capital Management investment in Dyne Therapeutics

Tip: Access up to 7 years of quarterly data

All positions including Dyne Therapeutics held by ADAR1 Capital Management consolidated in one spreadsheet with up to 7 years of data

Download as csvDownload consolidated filings csv Download as ExcelDownload consolidated filings xlsx

Quarterly reported holdings in Dyne Therapeutics by ADAR1 Capital Management

Quarter filed Position value Share count Share price at filing
2024-03-31 $8.4k 297 28.39

More positions owned by ADAR1 Capital Management

Alnylam Pharmaceuticals (ALNY)
Ea Series Trust Alpha Arch 1-3 (BOXX)
Roivant Sciences SHS (ROIV)
Spdr S&p 500 Etf Tr Tr Unit Put Option (SPY)
Protagonist Therapeutics (PTGX)
Cytokinetics Com New (CYTK)
Keros Therapeutics (KROS)
Royalty Pharma Shs Class A (RPRX)
Bridgebio Pharma (BBIO)
Merrimack Pharmaceuticals In Com New (MACK)
Ascendis Pharma A/s Sponsored Adr (ASND)
Arbutus Biopharma (ABUS)
Avrobio Ord (AVRO)
Beigene Sponsored Adr (BGNE)
Invesco Qqq Tr Unit Ser 1 Put Option (QQQ)

View all positions for ADAR1 Capital Management

Top funds holding Dyne Therapeutics

Atlas Venture Life Science Advisors
Fcpm Iii Services B.v.
BlackRock
RA Capital Management
Citadel Advisors
MPM Asset Management
Vanguard Group
FMR
Henderson Group
Adage Capital Partners GP
VR Adviser
Sofinnova Ventures
Franklin Resources
Logos Global Management
Goldman Sachs Group

View all funds holding Dyne Therapeutics